Houlihan Lokey Advises A&M Capital Europe

Houlihan Lokey is pleased to announce that A&M Capital Europe (AMCE) has acquired a majority stake in GBUK Group (GBUK or the company), a global provider of acute-setting medical devices, from H2 Equity Partners (H2EP). Houlihan Lokey served as exclusive M&A advisor to A&M Capital Europe.

Headquartered in the United Kingdom, GBUK designs, develops, and distributes a comprehensive portfolio of own and third-party branded acute-setting medical devices across enteral feeding, vascular access, patient handling, and the broader critical care environment. The company is a top-20 supplier to the UK's National Health Service (NHS) and supports healthcare professionals and patients in over 45 countries with more than 600,000 medical devices daily. GBUK has demonstrated a track record of penetrating new care areas by leveraging its R&D capabilities and a high-touch sales model hinging on wrap-around services.

AMCE is a London-headquartered, middle-market private equity investment firm specialising in building pan-European platform companies through buy-and-build in the middle market. AMCE Fund I currently has €650 million of assets under management, and GBUK represents AMCE’s 17th transaction. More broadly, AMCE is part of A&M Capital, a multi-strategy private equity investment firm with ~€4.5 billion in assets under management across four investment strategies. In addition, A&M Capital maintains a strategic association with Alvarez & Marsal, one of the world’s largest operationally focused advisory firms.

Houlihan Lokey served as the exclusive buyside advisor to A&M Capital Europe on this transaction. The terms of the transaction were not disclosed.